GlaxoSmithKline PLC (GSK)

42.95
NYSE : Health Care
Prev Close 42.95
Day Low/High 0.00 / 0.00
52 Wk Low/High 37.20 / 45.58
Avg Volume 2.92M
Exchange NYSE
Shares Outstanding 2.46B
Market Cap 105.64B
EPS 0.50
P/E Ratio 24.69
Div & Yield 1.95 (4.50%)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BKFS, CWAY, DE, EZPW, GSK, LMNX Downgrades: AMC, ESRT, MYOK, WERN Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Hikma Trims Full-Year Revenue Guidance After Advair Diskus Delay

Hikma Trims Full-Year Revenue Guidance After Advair Diskus Delay

Hikma Pharmaceuticals lowered its full year revenue guidance Friday after the U.S. Food & Drug Administration expressed concern over its generic Advair Diskus product.

Huge Downgrades Loom Over Hikma Pharmaceuticals

Huge Downgrades Loom Over Hikma Pharmaceuticals

Hikma could get hit with sizeable downgrades Friday when it updates the market with new guidance in the wake of the FDA's rejection of its generic Advair Diskus product

GlaxoSmithKline Could Buy Out Partner Novartis

GlaxoSmithKline Could Buy Out Partner Novartis

Novartis holds a 36.5% stake in the healthcare company.

Glaxit: GlaxoSmithKline Sees a Top Investor Dump Stock out of 'Frustration'

Glaxit: GlaxoSmithKline Sees a Top Investor Dump Stock out of 'Frustration'

GlaxoSmithKline shares traded firmly higher Friday after one of its biggest shareholders said he was dumping his holding after fifteen years out of "frustration".

Hikma Shares Plunge After It Says 'Low Likelihood' of 2017 Generic Advair Approval

Hikma Shares Plunge After It Says 'Low Likelihood' of 2017 Generic Advair Approval

Hikma shares plunged the most in nine months inLondon trading Thursday after the drugmaker said that approval of its generic Advair Diskus asthma treatment faces delays from the FDA.

European Stocks See Mixed Session as U.K.'s FTSE Leads

European Stocks See Mixed Session as U.K.'s FTSE Leads

European stock markets were mixed Wednesday's as investors responded to yet another raft earnings reports, company statements and comments from policy makers across the continent.

Mylan Unhappy With FDA Standards for Asthma Drug

Mylan Unhappy With FDA Standards for Asthma Drug

Earlier this year the FDA sent Mylan a letter saying it would not approve its drug.

Hikma Shares Slide Amid Speculation of FDA Ruling on Generic Advair

Hikma Shares Slide Amid Speculation of FDA Ruling on Generic Advair

Hikma Pharmaceuticals fell sharply in London ahead of a crucial decision by the U.S. Food & Drug Administration on whether to approve its generic Advair asthma treatment.

Relvar Ellipta Significantly Improved Asthma Control In Salford Lung Study Patients Compared With Their Usual Care

Relvar Ellipta Significantly Improved Asthma Control In Salford Lung Study Patients Compared With Their Usual Care

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva Inc (NASDAQ: INVA) today announced positive results from the innovative Salford Lung Study (SLS) in asthma, carried out amongst 4,233 patients treated by their own General...

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.

How Far Into the Drug Pipeline Should the FTC Reach?

How Far Into the Drug Pipeline Should the FTC Reach?

Novartis exec argues the FTC should keep its hands off when pharmaceutical products are in early stages of development.

How Much Did the YouTube Ad Boycott Cost Google in the First Quarter?

How Much Did the YouTube Ad Boycott Cost Google in the First Quarter?

Advertisers appear to be coming back to Alphabet's YouTube, but analysts are still likely to be skeptical on the company's Thursday earnings call.

European Benchmarks Lifted by Sluice of Strong Corporate Earnings

European Benchmarks Lifted by Sluice of Strong Corporate Earnings

From automakers to financials, strong corporate earnings numbers helped to boost major European benchmarks Wednesday, although stocks in Southern Europe fell on concerns over bank capital

Glaxo Stock Slumps as Investors Eye Advair Generics

Glaxo Stock Slumps as Investors Eye Advair Generics

Mylan's setback may not be enough to prevent generic Advair reaching the market in 2017

GlaxoSmithKline Beats Q1 Estimates, Keeps Full Year Targets In Place

GlaxoSmithKline Beats Q1 Estimates, Keeps Full Year Targets In Place

GlaxoSmithKline posted stronger-than-expected first quarter earnings and kept its full year profit and revenue figures in place as it awaits potential rivals to is Advair respiratory treatment.line

Can Anything Dent the Fox News Brand?

Can Anything Dent the Fox News Brand?

Two sexual harassment scandals might devastate other brands, but not so with Fox News.

These Stocks Are Showing Red Flags -- Here's When to Sell

These Stocks Are Showing Red Flags -- Here's When to Sell

You don't want to own these four 'toxic stocks'.

4 Stocks Are Showing Red Flags -- Here's When to Sell

4 Stocks Are Showing Red Flags -- Here's When to Sell

You don't want to own these four 'toxic stocks'.

Sarissa Lawsuit Likely After Innoviva Claims Win Over Dissidents

Sarissa Lawsuit Likely After Innoviva Claims Win Over Dissidents

Sarissa was seeking election of three nominees at the pharmaceutical company that the activist claims is being run for management's benefit.

How Badly Is the Bill O'Reilly Situation Hurting 21st Century Fox?

How Badly Is the Bill O'Reilly Situation Hurting 21st Century Fox?

As advertiser boycotts of 'The O'Reilly Factor' continue to grow, so do analysts' concerns about the network's bottom line. But the impact may be muted for now.

Murdochs Get European Approval for Sky Deal Despite Sexual Claims Against O'Reilly

Murdochs Get European Approval for Sky Deal Despite Sexual Claims Against O'Reilly

21st Century Fox still needs to get approval from U.K. regulators before it can close the $14.2 billion acquisition of the satellite TV and internet provider.

At Least 33 Companies Have Pulled Ads From 'The O'Reilly Factor' in Wake of Sexual Harassment Claims

At Least 33 Companies Have Pulled Ads From 'The O'Reilly Factor' in Wake of Sexual Harassment Claims

The list of major advertisers that have either removed their ads completely or shifted them away from Fox's popular primetime program, 'The O'Reilly Factor,' continues to grow.

GlaxoSmithKline Is Voluntarily Recalling Asthma Inhalers in the U.S.

GlaxoSmithKline Is Voluntarily Recalling Asthma Inhalers in the U.S.

GlaxoSmithKline is recalling some asthma inhalers due to a leak in the pump.

New Sexual and Racial Claims Against Fox News Increase Pressure on Younger Murdochs

New Sexual and Racial Claims Against Fox News Increase Pressure on Younger Murdochs

Several advertisers have withdrawn from Bill O'Reilly's show following A New York Times report tying him to payouts to quiet allegations of sexual harassment. Meanwhile, new racial cases have emerged.

Mylan Has Been Pounded, but the Pain May be Far from Over

Mylan Has Been Pounded, but the Pain May be Far from Over

The maker of the EpiPen seems incapable of overcoming its troubles.

Google's 'Very Very Very Small' Advertising Problem Is Anything but for Some Marketers

Google's 'Very Very Very Small' Advertising Problem Is Anything but for Some Marketers

Among others, GlaxoSmithKline, which suspended its ads from YouTube, said it will continue boycotting the site until Google can fully resolve its issues with offensive content.

VBI Vaccines Emerges as Strong Biotech Stock

VBI Vaccines Emerges as Strong Biotech Stock

Armed with an arsenal of vaccines in its product pipeline, this small biotech company is ready to rocket.